Cardio Diagnostics, a precision cardiovascular medicine company, has announced the start of in-house test processing at its new high-complexity CLIA-certified laboratory in Iowa City, Iowa. The facility is designed to support the company's proprietary epigenetic and genetic tests for coronary heart disease and other cardiovascular conditions.
The move is expected to reduce turnaround times for test results and improve operational efficiency, according to company statements. The lab's CLIA certification indicates it meets federal standards for clinical laboratory testing, ensuring quality and reliability.
Cardio Diagnostics has not disclosed the specific tests being processed initially, but its pipeline includes tests like Epi+Gen CHD, which assesses genetic and epigenetic markers for coronary heart disease. The company aims to expand access to advanced cardiac risk assessment tools.
This development comes as part of the company's broader strategy to vertically integrate its operations and enhance its commercial capabilities. The Iowa City lab is a key component in scaling up test volumes and supporting future growth.
